We are live on ! Find out more
EDSA icon

Edesa Biotech

9 hedge funds and large institutions have $42K invested in Edesa Biotech in 2017 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.01% less ownership

Funds ownership: 0.01%0% (-0.01%)

25% less funds holding

Funds holding: 129 (-3)

75% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 4

90% less capital invested

Capital invested by funds: $430K → $42K (-$388K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
9
Holders Change
-3
Holders Change %
-25%
% of All Funds
0.22%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
1
Increased
Reduced
2
Closed
4
Calls
Puts
Net Calls
Net Calls Change

EDSA Hedge Fund Activity: Q2 2017 in Review

9 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Edesa Biotech (EDSA) for Q2 2017, worth a combined $42K — down 90% from $430K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of EDSA and 1 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 0 added.

The largest buyer was UBS Group, opening a new position worth an estimated $6.41K. The largest seller was Anson Funds Management, exiting entirely with an estimated $300K sold.

  • 9 institutional investors held Edesa Biotech (EDSA) as of Q2 2017, down from 12 in Q1 2017.
  • Funds reported $42K of Edesa Biotech stock for Q2 2017, down 90% quarter-over-quarter.
  • 1 fund opened new Edesa Biotech positions in Q2 2017 and 4 closed out, a net change of -3 holders.
  • The largest Edesa Biotech buyer in Q2 2017 was UBS Group, an estimated $6.41K added.
  • The largest Edesa Biotech seller in Q2 2017 was Anson Funds Management, an estimated $300K sold.

Based on aggregated 13F filings for Q2 2017.